1. Home
  2. SHCO vs AUPH Comparison

SHCO vs AUPH Comparison

Compare SHCO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SHCO

Soho House & Co Inc.

HOLD

Current Price

$8.94

Market Cap

1.7B

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.84

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHCO
AUPH
Founded
1995
1993
Country
United Kingdom
Canada
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
SHCO
AUPH
Price
$8.94
$15.84
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$9.00
$17.25
AVG Volume (30 Days)
838.4K
1.6M
Earning Date
11-07-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.55
Revenue
$1,288,973,000.00
$265,808,000.00
Revenue This Year
$11.89
$21.22
Revenue Next Year
$7.87
$15.40
P/E Ratio
N/A
$28.81
Revenue Growth
8.48
20.62
52 Week Low
$4.77
$6.55
52 Week High
$8.95
$16.48

Technical Indicators

Market Signals
Indicator
SHCO
AUPH
Relative Strength Index (RSI) 67.95 59.93
Support Level $8.78 $15.15
Resistance Level $8.86 $16.03
Average True Range (ATR) 0.04 0.50
MACD 0.01 -0.13
Stochastic Oscillator 100.00 64.33

Price Performance

Historical Comparison
SHCO
AUPH

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: